Scholarlink

Background <p>Severe mental illness may affect health behaviors and outcomes during pandemics. Few studies have assessed whether people living with schizophrenia spectrum disorders (SSD) experienced adverse COVID-19 outcomes.</p> Methods <p>In a population-based historical cohort study comprising members of a health maintenance organization, we included 1273 patients with SSD and 12,730 age- and sex-matched controls tested for SARS-CoV-2 between March 2020 and May 2022. We assessed the association between schizophrenia and hospitalization, hospital length-of-stay, 30-day, and one-year mortality, constructing multiple linear regression and logistic regression models adjusting for sociodemographic factors, BMI, smoking, number of comorbidities, and vaccinations. We also assessed whether vaccination modified the association between schizophrenia and mortality.</p> Results <p>Among patients with SSD, 477 (37.5%) had a positive test, compared to 6203 (48.7%) in the comparison group. patients with SSD were at increased risk of hospitalization (adjusted odds ratio (OR<sub>adj</sub>) 3.44, 95% confidence interval (CI): 2.88–4.11, <i>p</i> &lt; 0.001); longer length-of-stay (β = 1.20, <i>p</i> &lt; 0.001); increased 30-day (OR<sub>adj</sub> 9.07, 95%CI 3.11–26.44); and one-year mortality (OR<sub>adj</sub> 6.27, 95%CI: 2.73–14.39). Further adjustment for vaccination altered the OR for 30-day mortality (OR<sub>adj</sub> 4.54, 95%CI: 1.54–13.38). Additionally, the association between schizophrenia and 30-day mortality was attenuated in strata of vaccinated (OR 4.79, 95%CI: 0.82–28.13, <i>p</i> = 0.082), vs. unvaccinated individuals (OR 7.53, 95%CI 2.19–25.92, <i>p</i> = 0.001), respectively.</p> Conclusions <p>In our cohort, patients with SSD experienced a significantly higher rate of hospitalization, length of stay, and mortality following a positive SARS-CoV-2 test, even after adjusting for important prognostic factors. COVID-19 vaccination modified these risks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long term outcomes after COVID-19 in patients with schizophrenia: a historical cohort study in a health maintenance organization

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月3日

查看全文
  • Gashaw Getaneh Dagnaw,
  • Ora Paltiel,
  • Asher Shafrir

摘要

Background

Severe mental illness may affect health behaviors and outcomes during pandemics. Few studies have assessed whether people living with schizophrenia spectrum disorders (SSD) experienced adverse COVID-19 outcomes.

Methods

In a population-based historical cohort study comprising members of a health maintenance organization, we included 1273 patients with SSD and 12,730 age- and sex-matched controls tested for SARS-CoV-2 between March 2020 and May 2022. We assessed the association between schizophrenia and hospitalization, hospital length-of-stay, 30-day, and one-year mortality, constructing multiple linear regression and logistic regression models adjusting for sociodemographic factors, BMI, smoking, number of comorbidities, and vaccinations. We also assessed whether vaccination modified the association between schizophrenia and mortality.

Results

Among patients with SSD, 477 (37.5%) had a positive test, compared to 6203 (48.7%) in the comparison group. patients with SSD were at increased risk of hospitalization (adjusted odds ratio (ORadj) 3.44, 95% confidence interval (CI): 2.88–4.11, p < 0.001); longer length-of-stay (β = 1.20, p < 0.001); increased 30-day (ORadj 9.07, 95%CI 3.11–26.44); and one-year mortality (ORadj 6.27, 95%CI: 2.73–14.39). Further adjustment for vaccination altered the OR for 30-day mortality (ORadj 4.54, 95%CI: 1.54–13.38). Additionally, the association between schizophrenia and 30-day mortality was attenuated in strata of vaccinated (OR 4.79, 95%CI: 0.82–28.13, p = 0.082), vs. unvaccinated individuals (OR 7.53, 95%CI 2.19–25.92, p = 0.001), respectively.

Conclusions

In our cohort, patients with SSD experienced a significantly higher rate of hospitalization, length of stay, and mortality following a positive SARS-CoV-2 test, even after adjusting for important prognostic factors. COVID-19 vaccination modified these risks.